Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.

被引：2
|
作者：
Gajria, D. [1 ]
King, T. A. [1 ]
Pannu, H. [1 ]
Sakr, R. [1 ]
Seidman, A. D. [1 ]
Syldor, A. [1 ]
Patil, S. [1 ]
Maybody, M. [1 ]
Norton, L. [1 ]
Rosen, N. [1 ]
Hudis, C. [1 ]
Chandarlapaty, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.574
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Challenges in the Management of Patients With HER2-Amplified Colorectal Cancer
    Brown, Timothy J.
    Massa, Ryan C.
    JCO ONCOLOGY PRACTICE, 2022, 18 (08) : 555 - +
  • [42] A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
    Pullarkat, V
    Deo, Y
    Link, J
    Spears, L
    Marty, V
    Curnow, R
    Groshen, S
    Gee, C
    Weber, JS
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1999, 48 (01) : 9 - 21
  • [43] A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
    V. Pullarkat
    Y. Deo
    J. Link
    L. Spears
    V. Marty
    R. Curnow
    S. Groshen
    C. Gee
    J. S. Weber
    Cancer Immunology, Immunotherapy, 1999, 48 : 9 - 21
  • [44] Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue
    Butterbaugh, S. T.
    Patel, R.
    Romond, E. H.
    Mathew, A.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3098 - 3099
  • [45] Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
    Verschoor, Noortje
    Smid, Marcel
    Jager, Agnes
    Sleijfer, Stefan
    Wilting, Saskia M.
    Martens, John W. M.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [46] Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
    Noortje Verschoor
    Marcel Smid
    Agnes Jager
    Stefan Sleijfer
    Saskia M. Wilting
    John W. M. Martens
    Breast Cancer Research, 25
  • [47] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.
    Mueller, Volkmar
    Riethdorf, Sabine
    Rack, Brigitte Kathrin
    Janni, Wolfgang
    Fasching, Peter A.
    Solomayer, Erich
    Aktas, Bahriye
    Kasimir-Bauer, Sabine
    Pantel, Klaus
    Fehm, Tanja N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers
    Joly, Meghan Morrison
    Hicks, Donna J.
    Jones, Bayley
    Sanchez, Violeta
    Estrada, Monica Valeria
    Young, Christian
    Williams, Michelle
    Rexer, Brent N.
    Sarbassov, Dos D.
    Muller, William J.
    Brantley-Sieders, Dana
    Cook, Rebecca S.
    CANCER RESEARCH, 2016, 76 (16) : 4752 - 4764
  • [50] Ado-trastuzumab for the treatment of metastatic HER2-amplified breast cancer patients previously treated with pertuzumab
    Al Rabadi, L. S.
    Kaempf, A.
    Lim, J. Y.
    Saraceni, M. M.
    Savin, M. A.
    Mitri, Z. I.
    CANCER RESEARCH, 2019, 79 (04)
12345